Cancer

Therapeutic target for gastric cancer

A protein kinase linked to inflammation and tumor development may be a good target for gastric cancer therapies.

Andries Zijlstra, Ph.D., and colleagues are studying a biomarker that can help predict prostate cancer recurrance. (photo by Susan Urmy)

Predictor of prostate cancer outcomes identified

Researchers at Vanderbilt University Medical Center and the University of Alberta in Canada have identified a biomarker for a cellular switch that accurately predicts which prostate cancer patients are likely to have their cancer recur or spread.

Therapeutic target for synovial sarcoma

Inhibitors of a signaling pathway that is critical to synovial sarcoma tumorigenesis may be useful treatments for this aggressive cancer.

Family’s support enhances cancer research training

John F. Brock III, chairman and CEO of Coca-Cola Enterprises, his wife, Mary, and their three children have established an endowment to support an oncology fellowship at Vanderbilt-Ingram Cancer Center. The Brock Family Fellowship will provide financial assistance long into the future for young physicians, postdoctoral students and medical investigators who are furthering their training in cancer research.

Molecular circuits in ovarian cancer

Vanderbilt researchers have used bioinformatics analysis of gene expression data to describe molecular “circuits” that drive ovarian cancer.

VU study sheds new light on DNA replication

David Cortez, Ph.D., and his Vanderbilt colleagues report new findings that shed light on fundamental processes involved in DNA replication and have implications for cancer therapies that target these processes.

1 54 55 56 57 58 71